Lilly ends development of Alzheimer's candidate solanezumab after study failure
jetcityimage/iStock Editorial via Getty Images
- Eli Lilly is ending development of Alzheimer's asset solanezumab after the biologic did not slow the progression of cognitive decline in individuals with a preclinical form of the disease.
- The study examined solanezumab in patients with amyloid plaque but no clinical Alzheimer's symptoms.
- "The A4 Study concludes our clinical development of solanezumab and indicates that targeting soluble amyloid beta through this mechanism is not effective in this population," said John Sims, Eli Lilly (NYSE:LLY) head of medical, global brand development – solanezumab.
- The end of solanezumab's development is not surprising given that it failed a phase 3 trial back in 2016.
- Lilly has two other late-stage Alzheimer's candidates, donanemab and remternetug. In January, the US FDA rejected the company's submission of an accelerated approval application for donanemab.